The genetic testing company and Future Biotechnology (Beijing) Co., Ltd. (hereinafter referred to as “People and the Futureâ€) have completed A-round financing of RMB 250 million in July this year. The investors are Jiawo Capital and Haijie Capital. The valuation has reached 2.75 billion yuan.
Founded in San Diego by a team of young North American scientists, the People and Future are conducting clinical research on genetic testing since 2009 and formally established in Beijing in 2014. The company focuses on genetic technology and combines other cutting-edge technologies such as information technology and machine learning, and is committed to technological innovation, application development and services in the fields of medicine and health. People and future NGS sequencing and bioinformatics solutions with independent intellectual property rights have successfully launched professional testing projects for tumor liquid biopsy, non-invasive prenatal, intestinal microbes, and susceptible genes, and developed the next generation bioinformatics computing platform (FPGA). Bioinformatics computing acceleration chip), text-based information analysis cloud service, realizes high-throughput sequencing technology and diversified industrial layout of computing applications in scientific research, clinical to health management.
People and future corporate businesses mainly include the following three items:
Medical diagnosis: With the help of genetic testing technology innovation and the transformation of medical genetics results, it provides decision-making basis for the individualized diagnosis and treatment of fetal chromosomal diseases, monogenic genetic diseases and cancer from the molecular biology level. Medical diagnosis mainly provides services for mothers and infants and provides individualized diagnosis and treatment of cancer. The core technology of liquid biopsy independently developed by the company, “ctBESTâ€, has a test sensitivity of 0.01%; the original “non-invasive monogenic disease screening†"Technology is also ready to go.
Smart Health Management: Integrate multi-dimensional vital signs data to create a healthy blueprint with group learning information; combine health medical decision support models and machine learning to create a complete product and platform system for disease risk individualized assessment and smart health management. People and the future not only provide genetic testing services such as susceptibility, intestinal micro-organisms, early tumor screening, but also incorporate the health management system of CDSS intelligent decision-making system, introduce machine intelligence diagnosis, and give the health management system expert-level diagnosis and treatment level and platform. Level of individualized intervention system.
Biomedical Big Data : Combining the technological advantages of its own BT+IT, it independently develops complete solutions across multiple aspects of big data, including high-performance data transmission, compression, storage, computing, interpretation and mining. Provide a full range of big data services at the world's top level.
After the financing, people and the future will accelerate the clinical transformation and marketing in the three sectors. Including: diagnosis and early screening reagents, cloud platform construction of big data services, industry user deployment, and application of precision health artificial intelligence platform, marketing promotion.
We're professional Proctology Instruments manufacturers and suppliers in China, specialized in providing high quality medical instruments with reasonable price. We warmly welcome you to buy or wholesale bulk Proctology Instruments for sale here and get quotation from our factory.
Proctology Instruments,Proctoscopy Instruments,Sigmoidoscopy Instruments,Sigmoidoscope Rectoscopy Instruments
Tonglu WANHE Medical Instrument Co., Ltd , https://www.tlvanhurhealth.com